

1 **Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine**

2 **Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial**

3 **Authors**

4 Prof Punnee Pitisuttithum, MD<sup>1</sup>, Viravarn Luvira, MD<sup>1</sup>, Saranath Lawpoolsri, MD<sup>1</sup>, Sant  
5 Muangnoicharoen, MD<sup>1</sup>, Supitcha Kamolratanakul, MD<sup>1</sup>, Chaisith Sivakorn, MD<sup>1</sup>, Piengthong Narakorn,  
6 MS<sup>2</sup>, Somchaiya Surichan, PhD<sup>2</sup>, Sumalee Prangpratanporn, MS<sup>2</sup>, Suttida Puksuriwong, PhD<sup>2</sup>, Steven  
7 Lamola, MD<sup>3</sup>, Laina D Mercer, PhD<sup>3</sup>, Rama Raghunandan, PhD<sup>3</sup>, Weina Sun, PhD<sup>4</sup>, Yonghong Liu, PhD<sup>4</sup>,  
8 Juan Manuel Carreño. PhD<sup>4</sup>, Rami Scharf, DSc<sup>3</sup>, Weerapong Phumratanaprapin, MD<sup>1</sup>, Fatima Amanat,  
9 PhD<sup>4</sup>, Luc Gagnon, PhD<sup>9</sup>, Ching-Lin Hsieh, PhD<sup>10</sup>, Ruangchai Kaweeponpoj, MS<sup>2</sup>, Sarwat Khan, MS<sup>9</sup>,  
10 Manjari Lal, PhD<sup>3</sup>, Stephen McCroskery, MS<sup>4</sup>, Prof Jason McLellan, PhD<sup>10</sup>, Ignacio Mena, PhD<sup>4,5</sup>, Marcia  
11 Meseck, MS<sup>7</sup>, Benjaluck Phonrat, MS<sup>1</sup>, Yupa Sabmee, MS<sup>1</sup>, Ratsamikorn Singchareon, MS<sup>2</sup>, Stefan  
12 Slamanig, MS<sup>4</sup>, Nava Suthepakul, MS<sup>2</sup>, Johnstone Tcheou, BS<sup>4</sup>, Narumon Thantamnu, BS<sup>1</sup>, Sompone  
13 Theerasurakarn, MS<sup>2</sup>, Steven Tran, MS<sup>9</sup>, Thanakrit Vilasmongkolchai, MS<sup>2</sup>, Jessica A White, PhD<sup>3</sup>, Prof  
14 Adolfo Garcia-Sastre, PhD<sup>4,5,6,7</sup>, Prof Peter Palese, PhD<sup>4,6</sup>, Prof Florian Krammer, PhD<sup>4,8</sup>, Kittisak  
15 Poopipatpol, BS<sup>2</sup>, Ponthip Wirachwong, PhD<sup>2</sup>, Richard Hjorth, PhD<sup>3</sup>, Bruce L Innis, MD<sup>3</sup>

16 **Author Affiliations:**

17 <sup>1</sup> Faculty of Tropical Medicine, Mahidol University, Faculty of Tropical Medicine, Mahidol University

18 420/6 Ratchawithi Road, Ratchathewi, Bangkok 10400. Thailand

19 <sup>2</sup> The Government Pharmaceutical Organization, 1 Thanon Rama VI, Thung Phaya Thai, Ratchathewi,

20 Bangkok 10400, Thailand

21 <sup>3</sup> PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA

22 <sup>4</sup> Department of Microbiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York,  
23 NY 10029, USA

24 <sup>5</sup> Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L.  
25 Levy Pl, New York, NY 10029, USA

26 <sup>6</sup> Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY  
27 10029, USA

28 <sup>7</sup> The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY  
29 10029, USA

30 <sup>8</sup> Department of Pathology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY  
31 10029, USA

32 <sup>9</sup> Nexelis, 525 Bd Cartier O, Laval, QC H7V 3S8, Canada

33 <sup>10</sup> College of Natural Sciences, The University of Texas at Austin, 120 Inner Campus Dr Stop G2500,  
34 Austin, TX 78712, USA

35 **Correspondence to:**

36 Bruce L Innis, MD, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA; [binnis@path.org](mailto:binnis@path.org)

37

38 ClinicalTrials.gov Identifier: NCT04764422

39 **Summary**

40 **Background**

41 Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income  
42 countries is needed. NDV-HXP-S is an inactivated egg-based Newcastle disease virus vaccine expressing  
43 the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It's being developed  
44 in Thailand, Vietnam, and Brazil; herein are initial results from Thailand.

45 **Methods**

46 This phase 1 stage of a randomised, dose-escalation, observer-blind, placebo-controlled, phase 1/2 trial  
47 was conducted at the Vaccine Trial Centre, Mahidol University (Bangkok). Healthy adults aged 18-59  
48 years, non-pregnant and negative for SARS-CoV-2 antibodies were eligible. Participants were block  
49 randomised to receive one of six treatments by intramuscular injection twice, 28 days apart: 1  
50  $\mu\text{g}\pm\text{CpG1018}$  (a toll-like receptor 9 agonist), 3  $\mu\text{g}\pm\text{CpG1018}$ , 10  $\mu\text{g}$ , or placebo. Participants and  
51 personnel assessing outcomes were masked to treatment. The primary outcomes were solicited and  
52 spontaneously reported adverse events (AEs) during 7 and 28 days after each vaccination, respectively.  
53 Secondary outcomes were immunogenicity measures (anti-S IgG and pseudotyped virus neutralisation).  
54 An interim analysis assessed safety at day 57 in treatment-exposed individuals and immunogenicity  
55 through day 43 per protocol. ClinicalTrials.gov (NCT04764422).

56 **Findings**

57 Between March 20 and April 23, 2021, 377 individuals were screened and 210 were enrolled (35 per  
58 group); all received dose one; five missed dose two. The most common solicited AEs among vaccinees,  
59 all predominantly mild, were injection site pain (<63%), fatigue (<35%), headache (<32%), and myalgia  
60 (<32%). The proportion reporting a vaccine-related AE ranged from 5.7% to 17.1% among vaccine  
61 groups and was 2.9% in controls; there was no vaccine-related serious adverse event. The 10  $\mu\text{g}$   
62 formulation's immunogenicity ranked best, followed by 3  $\mu\text{g}\pm\text{CpG1018}$ , 3  $\mu\text{g}$ , 1  $\mu\text{g}\pm\text{CpG1018}$ , and 1  $\mu\text{g}$

63 formulations. On day 43, the geometric mean concentrations of 50% neutralising antibody ranged from  
64 122·23 IU/mL (1 µg, 95% CI 86·40-172·91) to 474·35 IU/mL (10 µg, 95% CI 320·90-701·19), with 93·9% to  
65 100% of vaccine groups attaining a ≥4-fold increase over baseline.

#### 66 **Interpretation**

67 NDV-HXP-S had an acceptable safety profile and potent immunogenicity. The 3 µg and 3 µg+CpG1018  
68 formulations advanced to phase 2.

#### 69 **Funding**

70 National Vaccine Institute (Thailand), National Research Council (Thailand), Bill & Melinda Gates  
71 Foundation, National Institutes of Health (USA)

72

73 Word count = 353

74

75 **Introduction**

76 There remains a shocking imbalance in the global distribution of coronavirus disease 2019 (COVID-19)  
77 vaccines.<sup>1</sup> To achieve control of the COVID-19 pandemic in low- and middle-income countries (LMICs)  
78 where most of the global population resides, there must be a great increase in sustainable supply of  
79 affordable vaccines. The manufacturing capacity for egg-based inactivated influenza vaccines (IIV) is  
80 among the largest in the world; these facilities, some in middle-income countries and operating for less  
81 than six months per year, use locally produced embryonated eggs to make more than a billion doses  
82 annually of affordable human vaccines.<sup>2</sup> To enable these manufacturers to respond to the COVID-19  
83 pandemic, we developed a COVID-19 vaccine for production in eggs, based on a Newcastle disease virus  
84 (NDV) expressing the ectodomain of a novel membrane-anchored, prefusion-stabilized severe acute  
85 respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein construct, wherein virions are purified  
86 and inactivated (NDV-HXP-S).<sup>3-5</sup>

87 From September to November 2020, manufacturers in Thailand, Vietnam, and Brazil modified their IIV  
88 manufacturing process to optimize production of beta-propiolactone (BPL)-inactivated NDV-HXP-S,  
89 achieving high yields at pilot scale; the result was three similar processes. A preclinical evaluation of  
90 their vaccine candidates, formulated with and without CpG1018, a toll-like receptor 9 agonist adjuvant  
91 (Dynavax Technologies)<sup>6</sup> confirmed that they were highly immunogenic and protective in hamsters<sup>5</sup> with  
92 no sign of toxicity in rats at the maximum human doses planned for evaluation (3 µg S protein+1.5 mg  
93 CpG1018; 10 µg S protein). These results enabled all three manufacturers to initiate clinical  
94 development of their vaccine candidates. Herein, we report interim safety and immunogenicity data  
95 generated in the phase 1 portion of an adaptive phase 1/2 clinical trial evaluating the NDV-HXP-S  
96 vaccine candidate developed by The Government Pharmaceutical Organization of Thailand (GPO). These  
97 results provide the first evidence in humans that the NDV vector technology expressing a six-proline

98 prefusion-stabilized spike protein construct offers a unique platform for affordable manufacturing of a  
99 well-tolerated and highly immunogenic COVID-19 vaccine.

## 100 **Methods**

### 101 **Study design and participants**

102 The phase 1 segment of a randomised, observer-blind, placebo-controlled, phase 1/2 trial was  
103 conducted at the Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University (Bangkok,  
104 Thailand). Participants were recruited from individuals known to the Centre and through  
105 advertisements. Healthy adults 18–59 years of age with body mass index 17 to 40 kg/m<sup>2</sup>, -negative  
106 hepatitis B surface antigen and SARS-CoV-2, HIV, and hepatitis C antibody tests were eligible to  
107 participate. A negative urinary pregnancy test was required of women having reproductive capacity  
108 prior to administration of each study vaccine dose. Complete eligibility criteria are described in the trial  
109 protocol provided in the supplementary materials.

110 Written informed consent was obtained from all participants. The trial complied with the Declaration of  
111 Helsinki and Good Clinical Practice. This study was approved by the Ethics Committee of the Faculty of  
112 Tropical Medicine, Mahidol University (TMEC 21-005) and authorized by the Thailand Food and Drug  
113 Administration (FDA-21-018).

### 114 **Randomisation and masking**

115 Enrolled subjects were randomly assigned in sequence to one of 6 equal groups (vaccine containing 1 µg  
116 S ± 1.5mg CpG1018 adjuvant, 3 µg S ± 1.5mg CpG1018 adjuvant, 10 µg S, or saline placebo). Subjects  
117 were enrolled in stages, each including active treatment and placebo groups, using a computer-  
118 generated block randomisation sequence prepared by an independent statistician; an unblinded  
119 pharmacist team dispensed each treatment according to the randomization sequence. The first 18

120 subjects (sentinel cohort) were enrolled to three sequential sentinel groups; 3:1, 1 µg and placebo;  
121 3:3:1, 3 µg or 1 µg+CpG1018 and placebo; and 3:3:1, 10 µg or 3 µg+CpG1018 and placebo, After safety  
122 data were reviewed for the sentinel groups, the next 192 subjects were randomised in 5-dose-cohorts;  
123 32:6, 1 µg and placebo; 32:6, 3 µg and placebo; 32:6, 1 µg+CpG1018 and placebo; 32:7, 10 µg and  
124 placebo; and 32:7, 3 µg+CpG1018 and placebo. All participants and personnel other than the unmasked  
125 pharmacy team and vaccinators were masked to treatment.

## 126 **Procedures**

127 The recombinant NDV-HXP-S vaccine was manufactured according to current Good Manufacturing  
128 Practice by the GPO in their Influenza Vaccine Plant (Saraburi, Thailand) using locally procured  
129 embryonated eggs inoculated with a master virus seed made and extensively tested for adventitious  
130 agents by the Icahn School of Medicine at Mount Sinai (New York, USA). After incubation for 72 hours at  
131 37°C, eggs were chilled overnight at 4°C, then the allantoic fluids were harvested, clarified, and  
132 concentrated. Recombinant virus particles were purified from the concentrated harvest by two  
133 sequential continuous flow sucrose gradient centrifugations, diafiltered against phosphate-buffered  
134 saline (PBS), inactivated by treatment with 1:4000 BPL for 24 hours at 4°C, and 0.2 micron filter-  
135 sterilized. Vaccine potency was measured by direct enzyme-linked immunosorbent assay (ELISA) using a  
136 human monoclonal antibody (CR3022<sup>7</sup>) to SARS-CoV-2 spike glycoprotein S1 (LakePharma Inc) and an  
137 NDV-HXP-S standard that had been calibrated to a purified HXP-S reference<sup>8</sup> by sodium dodecyl sulphate  
138 polyacrylamide gel electrophoresis (SDS-PAGE) densitometry.

139 Unmasked staff administered study treatments by intramuscular injection of 0.5 mL on study days 1 and  
140 29. Blood samples were drawn and clinical assessments were done for safety and immunogenicity  
141 endpoints before vaccination on days 1 (dose one), 8, 29 (dose two), 36, and 43; a clinical assessment  
142 for safety only on day 57 was the last timepoint considered for this interim analysis of the phase 1

143 cohort, although there will be additional immunogenicity and safety assessments on study days 197 and  
144 365. Subjects were observed in the clinic for 30 minutes after each vaccination and were asked to record  
145 any adverse events using paper diary cards during the 7-days after each vaccination. Subjects randomly  
146 allocated to a cell-mediated immunity subset (N=12 per 10 µg, 3 µg+CpG1018, and placebo groups) had  
147 additional blood collected on days 1 and 43 for isolation of peripheral blood mononuclear cells (PBMCs);  
148 these were stored in liquid nitrogen until analysed.

149 Solicited injection site reactions (pain, tenderness, swelling, induration, erythema) and systemic  
150 symptoms (headache, fatigue, malaise, myalgia, arthralgia, nausea, vomiting, and fever defined as oral  
151 temperature  $\geq 38^{\circ}\text{C}$ ) were recorded by subjects in a diary card that included intensity, then reported by  
152 the investigators; these events were not assessed for causality. Subjects also recorded spontaneously  
153 reported adverse events (AEs) for 28 days; the investigator reported these after grading them for  
154 intensity and categorizing them as serious or not. The investigator also identified the following AEs of  
155 special interest: potential immune-mediated medical conditions (PIMMCs), and AEs of special interest  
156 associated with COVID-19. Intensity of AEs was graded 1-4 as follows: 1 or mild (minimal interference  
157 with daily activities), 2 or moderate (interferes with but does not prevent daily activities), 3 or severe  
158 (prevents daily activities, intervention required), and 4 or very severe (medical intervention required to  
159 prevent disability or death). Investigators assessed unsolicited adverse events for causality (related to  
160 vaccination or not). AEs were graded according to U.S. Department of Health and Human Services  
161 severity grading tables (Food and Drug Administration, Center for Biologics Evaluation and Research  
162 [September 2007] and National Institutes of Health, Division of AIDS [version 2.1, July 2017]). A protocol  
163 safety review committee regularly reviewed blinded safety data; a Data Safety Monitoring Board  
164 monitored unblinded safety data and recommended two formulations for advancing to phase 2.

165 We measured total anti-SARS-CoV-2 spike (S) IgG using a validated indirect ELISA at Nexelis (Laval,  
166 Canada). Purified recombinant SARS-CoV-2 pre-fusion spike (Nexelis) at 1µg/ml in phosphate buffered  
167 saline (PBS, Wisent Bioproducts) was adsorbed to 96 well Nunc Maxisorb microplates (Thermo Fischer  
168 Scientific) and blocked with 5% skim milk in PBS, containing 0.05% Tween 20. Serial dilutions of test  
169 samples and the assay standard plus controls were added in the plates and incubated for 60 minutes at  
170 room temperature (15-30°C). After washing, horseradish peroxidase (HRP) enzyme-conjugated goat  
171 anti-human IgG-Fc (Jackson ImmunoResearch Laboratories) was added for 60 minutes at room  
172 temperature (15-30°C), then washed. Bound secondary antibody was reacted with 3,3',5,5'-  
173 tetramethylbenzidine (TMB) ELISA peroxidase substrate (Bio-Rad Laboratories) and incubated for 30  
174 minutes at room temperature (15-30°C) before the reaction was stopped with 2N H<sub>2</sub>SO<sub>4</sub>. Plates were  
175 read at 450 nm with a correction at 620 nm to assess the level of anti-S IgG bound in the microtiter  
176 plate. A reference standard on each plate determined the quantity of anti-S IgG in arbitrary units  
177 (ELU/mL). Concentrations were transformed to binding antibody units per mL (BAU/mL), based on the  
178 WHO International Standard for anti-SARS-CoV-2 immunoglobulin,<sup>9</sup> using a conversion factor  
179 determined during assay validation (1/7-9815). The assay's cut-off and lower limit of quantitation (LLOQ)  
180 was 6.3 BAU/mL.

181 We measured serum neutralising activity against the Wuhan strain of SARS-CoV-2 in a validated  
182 pseudotyped virus neutralisation assay (PNA) that assessed particle entry-inhibition.<sup>10</sup> Briefly,  
183 pseudotyped virus particles containing a luciferase reporter for detection were made from a modified  
184 vesicular stomatitis virus (VSVΔG) backbone expressing the full-length spike glycoprotein of SARS-CoV-2  
185 (MN908947, Wuhan-Hu-1) from which the last 19 amino acids of the cytoplasmic tail were removed.<sup>11</sup>  
186 Seven two-fold serial dilutions of heat-inactivated serum samples were prepared in 96-well round-  
187 bottom transfer plates (Corning). Pseudotyped virus was added to the serum dilutions at a target

188 working dilution and incubated at 37°C with 5% CO<sub>2</sub> for 60 ± 5 minutes. Serum-virus complexes were  
189 then transferred onto 96 well white flat-bottom plates (Corning), previously seeded overnight with Vero  
190 E6 cells (Nexcelis) and incubated at 37°C and 5% CO<sub>2</sub> for 20 ± 2 hours. Following this incubation,  
191 luciferase substrate from ONE Glo™ Ex luciferase assay system (Promega) was added to the cells. Plates  
192 were then read on a SpectraMax® i3x plate reader (Molecular Devices) to quantify relative luminescence  
193 units (RLU), inversely proportional to the level of neutralising antibodies present in the serum. The  
194 neutralising titre of a serum sample was calculated as the reciprocal serum dilution corresponding to the  
195 50% neutralisation antibody titre (NT<sub>50</sub>) for that sample; the NT<sub>50</sub> titres were transformed to  
196 international units per mL (IU/mL), based on the WHO international standard for anti-SARS-CoV-2  
197 immunoglobulin, using a conversion factor determined during assay validation (1/1,872). The assay's  
198 cut-off and LLOQ were 5.3 IU/mL (10 as NT<sub>50</sub>) and 5.9 IU/mL, respectively. To benchmark vaccine  
199 immunogenicity assessed in BAU/mL and IU/mL, we used a panel of human convalescent serum samples  
200 (HCS) collected 14 days after symptom onset from consecutive cases of mild to moderate COVID-19  
201 illness among health care personnel seen as outpatients in Quebec, Canada during mid-2020. We also  
202 calculated 80% neutralisation titres (NT<sub>80</sub>); nevertheless, as the PNA was not validated for this  
203 measurement, these results are not presented. We used the same PNA assay to measure NT<sub>50</sub> (reported  
204 as titres) against pseudotyped virus particles generated for SARS-CoV-2 variants of concern B.1.315<sup>12</sup>  
205 and P.1<sup>13</sup>. In the absence of positive controls for the variant strains of SARS-CoV-2, we used control sera  
206 for the Wuhan-Hu-1 strain.

207 To assess cellular immunity, we quantified interferon-γ (IFN-γ) and IL-5 producing cells in PBMCs  
208 stimulated with SARS-CoV-2 spike peptide pools (vial 1 158 overlapping peptides, vial 2 157 overlapping  
209 peptides; JPT Peptide) using a human IFN-γ/IL-5 double-colour ELISpot kit (Cellular Technologies) in a  
210 qualified assay. Briefly, activated 96-well plates were coated with anti-human IFN-γ/IL-5 capture

211 antibodies at 2-8°C. Following overnight (>16h) coating, plates were washed with PBS, and stimulation  
212 media containing SARS-CoV-2 peptide pool 1 or peptide pool 2 or control media was added to wells,  
213 followed by the addition of PBMCs at  $2 \times 10^5$  cells/well. After an approximately 44-hour incubation at  
214  $37^\circ\text{C} \pm 1^\circ\text{C}$  with 5%  $\text{CO}_2$ , plates were washed to remove cells from the wells. Anti-human IFN- $\gamma$ /IL-5  
215 detection solution (containing anti-human IFN- $\gamma$  fluorescein isothiocyanate [FITC] and anti-human IL-5  
216 [biotin] detection antibodies) was then added to the wells and incubated at room temperature (15-30°C)  
217 for  $2 \text{ h} \pm 10 \text{ min}$  to detect IFN- $\gamma$  and IL-5 cytokine captured on the bottom of the well. Plates were  
218 washed, followed by the addition of a tertiary solution (containing FITC-HRP and streptavidin-alkaline  
219 phosphatase). Following incubation with the tertiary solution, plates were washed, and blue and red  
220 developer solutions were added in sequence (with washes in between), resulting in the appearance of  
221 blue (for IL-5) and red (for IFN- $\gamma$ ) spot forming units (SFUs) in proportion to T cell activity. SFUs were  
222 counted by an ImmunoSpot CTL Analyzer (using CTL ImmunoCapture Software (v7-0-14-0) and CTL  
223 ImmunoSpot Professional DC Analyzer (v7-0-28-2)). Readouts (one per peptide pool for IFN- $\gamma$ , one per  
224 peptide pool for IL-5) were expressed as number of SFU/ $10^6$  cells and combined as a ratio. The assay's  
225 LLOQ for IFN- $\gamma$  was 109 SFU/ $10^6$  cells and for IL-5 was 43 SFU/ $10^6$  cells.

## 226 **Outcome**

227 The primary outcomes were frequency and intensity of solicited injection site and systemic AEs during 7  
228 days after vaccination; frequency, intensity, and relatedness of clinically significant haematological and  
229 biochemical measurements at 7 days after each vaccination; frequency, intensity, and relatedness of  
230 unsolicited AEs during 28 days after each vaccination; and occurrence of medically-attended AEs, serious  
231 AEs, and AEs of special interest during the interim analysis period of 57 days after-first vaccination. The  
232 secondary immunogenicity outcomes were anti-S IgG and  $\text{NT}_{50}$  against Wuhan-1 strain SARS-CoV-2  
233 pseudotyped virus assessed on days 29 and 43 and expressed as geometric mean titre (GMT) or

234 concentration (GMCs, BAU/mL for ELISA, or IU/mL for PNA), geometric mean fold rise (GMFR) from  
235 baseline, and percentage of subjects with  $\geq 4$ -fold increase and  $\geq 10$ -fold increase from baseline. The  
236 exploratory immunogenicity outcomes were cell-mediated immunity to SARS-CoV-2 S protein, measured  
237 as the ratio of IFN- $\gamma$ /IL-5 expressing cells on days 1 and 43 in a random subset of subjects receiving two  
238 vaccine formulations (10  $\mu$ g or 3  $\mu$ g+CpG1018) or placebo. We also assessed NT<sub>50</sub> GMTs and the  
239 percentage of subjects with a NT<sub>50</sub> titre  $\geq 4$ -fold higher than the LLOQ (1:10 titre), against vaccine-  
240 heterologous SARS-CoV-2 pseudotyped virus (SARS-CoV-2 variants of concern B.1.351 and P.1) on day  
241 43.

## 242 **Statistical Analyses**

243 This Phase 1/2 study (ClinicalTrial.gov NCT04764422) has a two-part selection design with group  
244 elimination after the interim analysis. In the first part, 35 subjects per group were randomized across 5  
245 candidate vaccine formulations and a placebo group for a total of 210 subjects. After the interim  
246 analysis, two candidates were selected to advance, at which time 250 additional subjects are to be  
247 randomized 2:2:1 to the two selected candidate groups and the placebo, respectively. The study was  
248 designed to have greater than 90% power to identify the candidate with the highest response as  
249 measured by the NT<sub>50</sub> by ranked GMCs, assuming the true GMC is at least 1.5-fold larger than the  
250 second highest candidate group and to provide a preliminary safety evaluation of the candidates. An  
251 independent data monitoring committee provided safety oversight.

252 All statistical tests were two-sided with a significance level of 0.05. All statistical analyses were  
253 performed by an independent statistician using SAS version 9.4. All safety assessments took place in the  
254 treatment-exposed population, according to the treatment received. All subject-level percentages were  
255 supplemented with two-sided 95% confidence intervals computed via the Clopper-Pearson method. The  
256 analysis of immunogenicity was performed in the per protocol population, which excludes subjects with

257 protocol deviations that would affect the assessment. Immunogenicity data were descriptively analysed.  
258 Geometric mean antibody responses were reported by treatment and time point, accompanied by 95%  
259 CIs. The analysis of geometric means excluded subjects who were seropositive at baseline (defined by  
260 anti-S IgG >LLOQ as measured by ELISA). Geometric mean fold rises (GMFR) were calculated relative to  
261 baseline using the log difference of the paired samples, with corresponding CIs computed via the t-  
262 distribution, utilizing the antilog transformation to present the ratio. The proportions of subjects with  
263 GMFRs of  $NT_{50} \geq 4$  and  $\geq 10$  from baseline were summarized with 95% CIs. The analysis of  
264 immunogenicity relative to baseline included baseline seropositive subjects.

### 265 **Role of Funding Source**

266 The funders of the study had no role in data collection, data analysis, or writing of the statistical report.  
267 GPO was the clinical trial sponsor and approved the study protocol. GPO employees contributed as  
268 authors by preparing the investigational vaccine, interpreting data, and writing this report.

### 269 **Results**

270 Between March 22 and April 23, 2021, 210 healthy adults were enrolled and assigned to one of six  
271 treatment groups as shown in Figure 1. All received a first dose of vaccine or placebo; two subjects were  
272 excluded from receipt of a second dose (one became pregnant, one developed mild urticaria within 30  
273 minutes after dose one); three other subjects missed the day 29 visit and got no second dose. The  
274 baseline characteristics are shown by treatment group in table 1; the exposed population was 61%  
275 female, had a median age of 36 years (IQR 28, 43) and a median body mass index of 24.07 (IQR 21.30-  
276 26.72).

277 All five formulations of NDV-HXP-S were well tolerated with no dose limiting reactogenicity (Table 2).  
278 Most solicited injection site and systemic reactogenicity during 7 days after each vaccination was mild  
279 and transient with no apparent difference between dose 1 and 2. The most common injection site

280 symptoms (table 2) were pain and tenderness; these were most frequent at the highest dose. The most  
281 common systemic symptoms (table 2) were fatigue, headache, and myalgia, generally in less than one-  
282 third of subjects. Fever was uncommon. Adverse events occurring during 28 days after vaccination (table  
283 3) and judged by the investigator to be treatment-related were infrequent (<15%) and there was no  
284 treatment-related serious adverse event, nor any AE of special interest reported during the 57 day  
285 assessment period. Haematology and serum chemistry laboratory readouts were assessed on day 8  
286 following each vaccination; there was no clinically notable finding relative to baseline assessment. The  
287 independent data monitoring committee expressed no safety concern.

288 Two doses of NDV-HXP-S were immunogenic in a formulation and dose dependent manner within the  
289 per protocol population. Induction of anti-S IgG was modest following dose one but there was a marked  
290 anamnestic response observed 14 days after vaccine dose two (figure 2A). Seronegative individuals in  
291 the vaccine groups responded 28 days after first vaccination with GMCs of anti-S IgG between 7.79 (1  
292  $\mu\text{g}$ ) and 20.93 (10  $\mu\text{g}$ ) BAU/mL, with a  $\geq 4$ -fold increase in 34.3-71.4%. The second dose considerably  
293 increased anti-S-IgG antibody responses after 14 days to GMCs between 151.78 (1  $\mu\text{g}$ ) and 479.83 (10  
294  $\mu\text{g}$ ) BAU/mL. All individuals in every vaccine group had a  $\geq 4$ -fold increase over baseline after the second  
295 dose; all individuals in the 10  $\mu\text{g}$  and 3  $\mu\text{g}$ +CpG1018 groups had a  $\geq 10$ -fold increase, as did >90% of  
296 vaccinees in the other three vaccine groups (figure 2C). Notably, the adjuvant effect of CpG was limited  
297 after two vaccine doses (table 4): the 1  $\mu\text{g}$  group had a GMC of 151.78 BAU/mL (95% CI 108.99-211.37)  
298 while the 1  $\mu\text{g}$ +CpG1018 group had a GMC of 199.08 BAU/mL (95% CI 140.25-282.57). Among recipients  
299 of the 3  $\mu\text{g}$  dose, the GMC group difference appeared to be greater: 228.07 BAU/mL (no adjuvant, 95%  
300 CI 154.22-337.27) in contrast to 356.83 BAU/mL (CpG1018, 95% CI (265.89-478.88). GMCs of anti-S IgG  
301 among the vaccine groups on day 43 exceeded the GMC of the HCS panel (N=29, 72.93 95% CI 33.00-  
302 161.14) by 2-6-fold (table 4).

303 Functional antibody responses were assessed by PNA. Low NT<sub>50</sub> GMCs were detected in all vaccine  
304 groups after the first vaccination (between 7·49 IU/mL and 12·82 IU/mL) with ≥4-fold rises in 8·8% to  
305 25·7% of the vaccine groups (figure 2B ,2D). The second vaccine dose strongly boosted neutralisation  
306 GMCs to between 122·23 IU/mL (1 µg, 95% CI 86·40-172·91) and 474·35 IU/mL (10 µg, 95% CI 320·90-  
307 701·19), with a ≥4-fold increase over baseline in 93·9% to 100% of vaccine groups and a ≥10-fold rise in  
308 most individuals (100% in the 10 µg group, and between 79·4% and 93·9% in the remaining groups). The  
309 differences in post-second dose GMCs between the unadjuvanted and adjuvanted 1 µg and 3 µg groups  
310 were uncertain: 1 µg, 122·23 IU/mL (95% CI 86·40-172·91) versus 1 µg+CpG1018, 127·92 IU/mL (95% CI  
311 85·08-192·34); 3 µg, 166·54 IU/m: (95% CI 100·19-276·81) versus 3 µg+CpG1018 257·70 IU/mL (95% CI  
312 187·01-355·11).

313 Based on the vaccine-homologous binding and neutralising antibody responses, there was a clear  
314 ranking of immunogenicity with the 10 µg formulation performing best followed by the 3 µg+CpG1018,  
315 3 µg, 1 µg+CpG1018 and 1 µg formulations. The induction of humoral immunity was strong with post-  
316 boost GMFRs relative to baseline of 48-fold (1 µg) to 152-fold (10 µg) for anti-S IgG and 46-fold (1 µg) to  
317 174-fold (10 µg) for NT<sub>50</sub> antibodies (figure 3). GMCs of NT<sub>50</sub> by PNA among the vaccine groups on day 43  
318 exceeded the GMC of the HCS panel (N=32, 36·30 95% CI 19·43-67·79) by 3-13-fold depending on the  
319 vaccine formulation (table 4).

320 Additionally, neutralisation of variant viruses was assessed by PNA on day 43. The proportion of subjects  
321 attaining a day 43 NT<sub>50</sub> titre ≥40 increased with higher doses of antigen but the incremental changes in  
322 GMT were small. Reduction in neutralising potency, relative to anti-Wuhan neutralising potency, was  
323 modest for the P.1 variant (2·8 to 5·3-fold) but greater for the B·1·351 variant (7·41 to 20·43-fold) (figure  
324 4, table 5). In groups receiving 3 µg or 10 µg antigen doses, the proportion attaining a NT<sub>50</sub> titre ≥40  
325 ranged from 80·0% to 94·9% against P.1 and from 43·3% to 58·5% against B.1.351 (table 5). Finally, we

326 also explored T cell responses to determine if the vaccine induced primarily a type 1 (T<sub>H</sub>1) or type 2 (T<sub>H</sub>2)  
327 T-helper cell response. In the small subset of subjects evaluated 14 days after a second dose, the IFN-  
328  $\gamma$ /IL-5 ratio was strongly skewed to a T<sub>H</sub>1 response relative to pre-vaccination baseline (figure 5),  
329 suggesting the vaccine induced T cell memory capable of an antiviral response.

## 330 **Discussion**

331 Current production capacity cannot satisfy the global demand for COVID-19 vaccines<sup>1</sup> and vaccine  
332 distribution is inequitable with most vaccines acquired and used by high income countries while LMICs  
333 have limited access. Local production of COVID-19 vaccines in LMICs would increase global availability  
334 and reduce dependence of countries producing these vaccines on international vaccine supply. Here we  
335 demonstrated for the first time that an engineered inactivated NDV-based vaccine expressing a second-  
336 generation stabilized SARS-CoV-2 spike protein<sup>5</sup>, produced in eggs in an existing influenza virus  
337 production facility at GPO in Thailand, shows an acceptable reactogenicity and safety profile in humans  
338 and has immunogenicity that supports its potential clinical benefit. We evaluated a range of vaccine  
339 doses (1  $\mu$ g, 3  $\mu$ g, 10  $\mu$ g) having potency quantified as  $\mu$ g of virus envelope-anchored SARS-CoV-2 spike  
340 protein; the low and medium antigen doses were evaluated in formulations with and without the TLR-9  
341 agonist CpG1018 as a vaccine adjuvant. Over 28 days after each vaccine dose, all formulations were very  
342 well-tolerated with little solicited injection site or systemic reactogenicity aside from mild injection site  
343 pain and tenderness. There was no safety signal issuing from this early interim analysis of the clinical  
344 trial. Moreover, the vaccine was strongly immunogenic in a formulation and dose dependent manner,  
345 inducing levels of vaccine-homologous anti-S IgG and virus neutralising antibodies that exceeded by  
346 several fold the levels measured in 14-day convalescent sera from consecutive cases of health care  
347 workers with mild to moderate COVID-19 illness in 2020. Notably, the adjuvant benefit as measured by  
348 enhanced induction of humoral immunity was uncertain, as the small sample size limited precision. On  
349 the other hand, the vaccine at all dose levels elicited neutralising antibodies against two variants of

350 concern, B.1.351 and P.1. While neutralising antibody titres decreased modestly against P.1 and more  
351 markedly against B.1.351, this was expected and in the range observed with sera from recipients of the  
352 mRNA vaccines BNT162b2 and mRNA-1273.<sup>14-17</sup> The degree of reduction in neutralisation is dependent  
353 on the assay used and can be especially dramatic with pseudotyped particle inhibition assays as used in  
354 this study.<sup>14,17</sup> Notably, the B.1.351 variant is currently regarded as a worst case example of immune  
355 evasion; accordingly, the NDV-HXP-S would be predicted to have neutralising activity against the now  
356 prevalent delta (B.1.617.2) variant. The T cell response assessed showed a bias towards a T<sub>H</sub>1 response  
357 in both evaluated dose groups, alleviating concerns about enhanced disease associated with a T<sub>H</sub>2  
358 response (as observed with SARS-CoV-1 in some animal models<sup>18</sup>). These initial data, while sparse,  
359 suggest the vaccine-induced T cell memory capable of an antiviral response.

360 The study has several limitations. The sample size per treatment group was small, limiting precision, and  
361 assessments were restricted to 43 days for immunogenicity and 57 days for reactogenicity and safety,  
362 narrowing our perspective to acute outcomes only. These are inherent problems of phase 1 trials and  
363 interim analyses in a pandemic response setting. Nevertheless, as clinical trials with similar vaccines are  
364 underway in Vietnam (NCT04830800) and Brazil (NCT04993209), we determined that publication of  
365 early data is a priority. The study had strengths as well. The vaccine construct is a novel platform  
366 expressing a second-generation pre-fusion stabilized S protein in a membrane-bound trimeric  
367 conformation. We hypothesize that these characteristics contribute to the vaccine's notable  
368 immunogenicity, even without the CpG1018 adjuvant. The anti-S ELISA and PNA used to assess vaccine-  
369 homologous NT<sub>50</sub> potency were validated and results are expressed in International Units<sup>9</sup> for future  
370 comparisons. The induction of anti-S binding and neutralising antibodies was contrasted with mean  
371 levels in human convalescent serum and found to be superior, especially in the mid- and high-dose  
372 groups. However, the neutralisation assay is not a live virus assay; therefore, it is presently uncertain  
373 how our functional antibody readouts can be used to benchmark against live virus neutralising antibody

374 levels induced by authorized or licensed vaccines. Correlation between neutralising antibody titres and  
375 vaccine efficacy and individual protection has recently been shown; work is ongoing to integrate these  
376 data into this analytic framework.<sup>19-21</sup> On the other hand, mean vaccine anti-S IgG ELISA responses  
377 normalized by the mean in convalescent sera as proposed by Earle and others<sup>19</sup> suggest that the NDV-  
378 HXP-S vaccine will afford important clinical benefit. Furthermore, we plan to conduct a clinical trial in  
379 which the NDV-HXP-S vaccine will be contrasted to an authorized comparator vaccine to generate  
380 relative immunogenicity evidence that may be predictive of clinical benefit.

381 In summary, we show that the inactivated NDV-HXP-S vaccine candidate has an acceptable safety profile  
382 and is highly immunogenic. This vaccine can be produced at low cost in any facility designed for  
383 production of inactivated influenza virus vaccine; such facilities are present in a number of LMICs.<sup>2</sup>  
384 Based on these results, and acknowledging the imperative to maximize output of vaccine doses from the  
385 manufacturing facility, the 3 µg and 3 µg+CpG1018 formulations were selected for further assessment in  
386 the phase 2 stage of the ongoing clinical trial.

387 Word count 4,361

388

389 **Contributors**

390 PPit and SLaw verified the underlying data reported herein. All authors had full access to all the data in  
391 the study. Individual author roles are reported using CRediT: Conceptualisation, PPit, SLam, LDM, RSch,  
392 AGS, PPal, FK, KP, PW, and BLI; Data curation, PPit and SLaw; Formal analysis, Slaw, LDM, JMC, and JT;  
393 Funding acquisition, PN, SSur, RR, NS, AGS, PPal, FK, KP, PW, and BLI; Investigation, PPit, VL, SM, SKam,  
394 CS, WS, YL, WP, FA, LG, SKha, SM, IM, BP, SSla, and STra; Methodology, PPit, VL, SM, PN, SSur, SPra,  
395 SPuk, SLam, LDM, RR, WS, YL, FA, LG, RK, SKha, ML, IM, BP, RSin, NS, SThe, STra, TV, JAW, FK, and RH,  
396 Project administration, PPit, PN, SSur, RSch, YS, NS, NT, TV, and PW; Resources, PPit, SPra, SPuk, WS,  
397 CLH, ML, JSM, RSin, SThe, JAW, AGS, PPal, FK, and RH; Supervision, PPit, SPra, RR, RSch, LG, RK, ML, JAW,  
398 AGS, PPal, FK, KP, PW, and BLI; Validation, SLaw, SPra, SPuk, LG, RK, SKha, RSin, SThe, and STra;  
399 Visualisation, LDM, JMC, JT, and BLI; Writing—original draft, LDM, RR, FK, and BLI; Writing—review &  
400 editing, PPit, VL, SLaw, SM, SKam, CS, SSur, SPuk, SLam, WS, JMC, RSch, FA, LG, CLH, RK, SKha, ML, JSM,  
401 IM, JT, STra, JAW, PW, and RH.

402 **Declaration of Interest**

403 PN, SSur, SPra, SPuk, RK, RSin, NS, SThe, TV, KP, and PW are salaried employees of the Government  
404 Pharmaceutical Organization. The vaccine administered in this study was developed by faculty members  
405 at the Icahn School of Medicine at Mount Sinai including FK, AGS, PP, and WS. Mount Sinai is seeking to  
406 commercialize this vaccine; therefore, the institution and its faculty inventors could benefit financially.  
407 JSM and CLH are inventors on U.S. patent applications concerning the stabilized SARS-CoV-2 S construct.

408 **Data sharing**

409 Under review, to be decided by the sponsor prior to publication.

410

411 **Acknowledgements**

412 Activities at PATH and Mount Sinai were supported, in part, by the Bill & Melinda Gates Foundation  
413 [INV-021239]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0  
414 Generic License has already been assigned to the Author Accepted Manuscript version that might arise  
415 from this submission. The findings and conclusions contained within this manuscript are those of the  
416 authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. The  
417 salary of PP was partially funded by NIH (Centers of Excellence for influenza Research and Response,  
418 CEIRR,75N93021C00014), NIAID grant (P01 AI097092-07), NIAID grant (R01 AI145870-03), by the NIH  
419 Collaborative Influenza Vaccine Innovation Centers (CIVICs) contract 75N93019C00051 and a grant from  
420 an anonymous philanthropist to Mount Sinai. Design and generation of reagents used in this project in  
421 the Krammer laboratory were supported by CEIRR (75N93021C00014) and CIVIC (75N93019C00051).  
422 Research and development activities in Thailand were funded by the Government Pharmaceutical  
423 Organization Thailand), the National Vaccine Institute (Thailand), and the National Research Council  
424 (Thailand). Testing of clinical trial specimens at Nexelis was supported by the Global Health Vaccine  
425 Accelerator Platform of the Bill & Melinda Gates Foundation. The authors thank Dr. Randy Albrecht for  
426 management of import/export of Newcastle disease virus vectors at the Icahn School of Medicine at  
427 Mount Sinai. We are grateful to Dr. Nina Bardwaj for programmatic and scientific oversight of the Virus  
428 and Cell Therapy Laboratory at the Icahn School of Medicine at Mount Sinai, which produced the NDV-  
429 HXP-S master virus seed.  
430

## 431 References

- 432 1. (WHO) WHO. [https://www.who.int/director-general/speeches/detail/director-general-s-](https://www.who.int/director-general/speeches/detail/director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-9-april-2021)  
433 opening-remarks-at-the-media-briefing-on-covid-19-9-april-2021. 2021.
- 434 2. Sparrow E, Wood JG, Chadwick C, et al. Global production capacity of seasonal and pandemic  
435 influenza vaccines in 2019. *Vaccine* 2021; **39**(3): 512-20.
- 436 3. Sun W, McCroskery S, Liu WC, et al. A Newcastle Disease Virus (NDV) Expressing a Membrane-  
437 Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. *Vaccines (Basel)* 2020; **8**(4).
- 438 4. Hsieh CL, Goldsmith JA, Schaub JM, et al. Structure-based design of prefusion-stabilized SARS-  
439 CoV-2 spikes. *Science* 2020; **369**(6510): 1501-5.
- 440 5. Sun W, Liu Y, Amanat F, et al. A Newcastle disease virus-vector expressing a prefusion-stabilized  
441 spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants  
442 of concern in mice and hamsters. *bioRxiv* 2021: 2021.07.06.451301.
- 443 6. Campbell JD. Development of the CpG Adjuvant 1018: A Case Study. *Methods Mol Biol* 2017;  
444 **1494**: 15-27.
- 445 7. ter Meulen J, van den Brink EN, Poon LL, et al. Human monoclonal antibody combination against  
446 SARS coronavirus: synergy and coverage of escape mutants. *PLoS Med* 2006; **3**(7): e237.
- 447 8. Hsieh CL, Goldsmith JA, Schaub JM, et al. Structure-based design of prefusion-stabilized SARS-  
448 CoV-2 spikes. *Science* 2020.
- 449 9. Kristiansen PA, Page M, Bernasconi V, et al. WHO International Standard for anti-SARS-CoV-2  
450 immunoglobulin. *Lancet* 2021; **397**(10282): 1347-8.
- 451 10. Bewley KR, Coombes NS, Gagnon L, et al. Quantification of SARS-CoV-2 . neutralising antibody by  
452 wild-type plaque reduction neutralisation, microneutralisation and pseudotyped virus neutralisation  
453 assays. *Nat Protoc* 2021; **16**(6): 3114-40.
- 454 11. Havranek KE, Jimenez AR, Acciani MD, et al. SARS-CoV-2 Spike Alterations Enhance  
455 Pseudoparticle Titers and Replication-Competent VSV-SARS-CoV-2 Virus. *Viruses* 2020; **12**(12).
- 456 12. Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in  
457 South Africa. *Nature* 2021; **592**(7854): 438-43.
- 458 13. Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of the P.1 SARS-CoV-2  
459 lineage in Manaus, Brazil. *Science* 2021; **372**(6544): 815-21.
- 460 14. Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape neutralisation  
461 by vaccine-induced humoral immunity. *Cell* 2021; **184**(9): 2523.
- 462 15. Carreño JM, Alshammary H, Singh G, et al. Reduced . neutralising activity of post-SARS-CoV-2  
463 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37. *medRxiv*  
464 2021: 2021.07.21.21260961.

- 465 16. Edara VV, Norwood C, Floyd K, et al. Infection- and vaccine-induced antibody binding and  
466 neutralisation of the B.1.351 SARS-CoV-2 variant. *Cell Host Microbe* 2021; **29**(4): 516-21.e3.
- 467 17. Shen X, Tang H, Pajon R, et al. Neutralisation of SARS-CoV-2 Variants B.1.429 and B.1.351. *N Engl*  
468 *J Med* 2021; **384**(24): 2352-4.
- 469 18. Krammer F. SARS-CoV-2 vaccines in development. *Nature* 2020; **586**(7830): 516-27.
- 470 19. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate  
471 for COVID-19 vaccines. *Vaccine* 2021.
- 472 20. Khoury DS, Cromer D, Reynaldi A, et al. . neutralising antibody levels are highly predictive of  
473 immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 2021.
- 474 21. Gilbert PB, Montefiori DC, McDermott A, et al. Immune Correlates Analysis of the mRNA-1273  
475 COVID-19 Vaccine Efficacy Trial. *medRxiv* 2021: 2021.08.09.21261290.
- 476

477 Table 1. Baseline characteristics of the exposed population

	<b>1 µg S (N = 35)</b>	<b>1 µg S+CpG (N = 35)</b>	<b>3 µg S (N = 35)</b>	<b>3 µg S+CpG (N = 35)</b>	<b>10 µg S (N = 35)</b>	<b>Placebo (N = 35)</b>
Age, years	33·0 (26·0- 39·0)	39·0 (32·0- 45·0)	37·0 (29·0- 49·0)	34·0 (25·0- 44·0)	37·0 (31·0- 42·0)	32·0 (27·0- 42·0)
Sex						
Male	14 (40·0%)	14 (40·0%)	7 (20·0%)	15 (42·9%)	18 (51·4%)	14 (40·0%)
Female	21 (60·0%)	21 (60·0%)	28 (80·0%)	20 (57·1%)	17 (48·6%)	21 (60·0%)
Ethnicity						
Asian	35 (100%)	35 (100%)	35 (100%)	35 (100%)	35 (100%)	35 (100%)
Body mass index	24·59 (20·76- 27·85)	24·85 (21·42- 26·33)	23·95 (21·23- 27·96)	23·95 (21·70- 25·92)	24·52 (21·26- 27·68)	23·12 (21·72- 27·22)

478 Data are median (q1-q3) or n (%)

479

480 Table 2. Solicited AEs during 7 days after vaccination

		<b>1 µg S</b> <b>(N = 35)</b>	<b>1 µg S+CpG</b> <b>(N = 35)</b>	<b>3 µg S</b> <b>(N = 35)</b>	<b>3 µg S+CpG</b> <b>(N = 35)</b>	<b>10 µg S</b> <b>(N = 35)</b>	<b>Placebo</b> <b>(N = 35)</b>
		<b>n (%)</b> <b>(95% CI)</b>	<b>n (%)</b> <b>(95% CI)</b>	<b>n (%)</b> <b>(95% CI)</b>	<b>n (%)</b> <b>(95% CI)</b>	<b>n (%)</b> <b>(95% CI)</b>	<b>n (%)</b> <b>(95% CI)</b>
Any injection site AE	Dose 1	8 (22.9%) (10.4-40.1)	13 (37.1%) (21.5-55.1)	14 (40.0%) (23.9-57.9)	20 (57.1%) (39.4-73.7)	23 (65.7%) (47.8-80.9)	4 (11.4%) (3.2-26.7%)
	Dose 2	10 (28.6%) (14.6-46.3)	14 (42.4%) (25.5-60.8)	16 (47.1%) (29.8-64.9)	20 (58.8%) (40.7-75.4)	24 (68.6%) (50.7-83.1)	10 (29.4%) (15.1-47.5)
Pain	Dose 1	2 (5.7%) (0.7-19.2)	8 (22.9%) (10.4-40.1)	10 (28.6%) (14.6-46.3)	16 (45.7%) (28.8-63.4)	16 (45.7%) (28.8-63.4)	3 (8.6%) (1.8-23.1)
	Dose 2	10 (28.6%) (14.6-46.3)	10 (28.6%) (14.6-46.3)	15 (42.9%) (26.3-60.6)	17 (48.6%) (31.4-66.0)	22 (62.9%) (44.9-78.5)	8 (22.9%) (10.4-40.1)
Tenderness	Dose 1	6 (17.1%) (6.6-33.6)	4 (11.4%) (3.2-26.7)	4 (11.4%) (3.2-26.7)	4 (11.4%) (3.2-26.7)	7 (20.0%) (8.4-36.9)	1 (2.9%) (0.1-14.9)
	Dose 2	0 (0.0%) (0.0-10.0)	4 (11.4%) (3.2-26.7)	1 (2.9%) (0.1-14.9)	3 (8.6%) (1.8-23.1)	2 (5.7%) (0.7-19.2)	2 (5.7%) (0.7-19.2)
Swelling	Dose 1	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)
	Dose 2*	masked	masked	masked	masked	masked	masked
Induration	Dose 1	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)
	Dose 2	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)
Erythema	Dose 1	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)
	Dose 2	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

		(0·0-10·0)	(0·0-10·0)	(0·0-10·0)	(0·0-10·0)	(0·0-10·0)	(0·0-10·0)
Any systemic AE	Dose 1	12 (34·3%) (19·1-52·2)	8 (22·9%) (10·4-40·1)	19 (54·3%) (36·6-71·2)	14 (4·0%) (23·9-57·9)	17 (48·6%) (31·4-66·0)	7 (20·0%) (8·4-36·9)
	Dose 2	9 (25·7%) (12·5-43·3)	11 (33·3%) (18·0-51·8)	9 (26·5%) (12·9-44·4)	17 (50·0%) (32·4-67·6)	15 (42·9%) (26·3-60·6)	4 (11·8%) (3·3-2·5)
Fever >38°C	Dose 1	0 (0·0%) (0·0-10·0)	0 (0·0%) (0·0-10·0)	1 (2·9%) (0·1-14·9)	0 (0·0%) (0·0-10·0)	3 (8·6%) (1·8-23·1)	0 (0·0%) (0·0-10·0)
	Dose 2	0 (0·0%) (0·0-10·0)	0 (0·0%) (0·0-10·0)	1 (2·9%) (0·1-14·9)	2 (5·7%) (0·7-19·2)	2 (5·7%) (0·7-19·2)	0 (0·0%) (0·0-10·0)
Headache	Dose 1	5 (14·3%) (4·8-30·3)	5 (14·3%) (4·8-30·3)	9 (25·7%) (12·5-43·3)	6 (17·1%) (6·6-33·6)	11 (31·4%) (16·9-49·3)	1 (2·9%) (0·1-14·9)
	Dose 2	4 (11·4%) (3·2-26·7)	5 (14·3%) (4·8-30·3)	6 (17·1%) (6·6-33·6)	8 (22·9%) (10·4-40·1)	4 (11·4%) (3·2-26·7)	1 (2·9%) (0·1-14·9)
Fatigue	Dose 1	8 (22·9%) (10·4-40·1)	4 (11·4%) (3·2-26·7)	12 (34·3%) (19·1-52·2)	6 (17·1%) (6·6-33·6)	6 (17·1%) (6·6-33·6)	7 (20·0%) (8·4-36·9)
	Dose 2	3 (8·6%) (1·8-23·1)	6 (17·1%) (6·6-33·6)	7 (20·0%) (8·4-36·9)	8 (22·9%) (10·4-40·1)	7 (20·0%) (8·4-36·9)	4 (11·4%) (3·2-26·7)
Malaise	Dose 1	1 (2·9%) (0·1-14·9)	1 (2·9%) (0·1-14·9)	1 (2·9%) (0·1-14·9)	3 (8·6%) (1·8-23·1)	4 (11·4%) (3·2-26·7)	0 (0·0%) (0·0-10·0)
	Dose 2	1 (2·9%) (0·1-14·9)	1 (2·9%) (0·1-14·9)	1 (2·9%) (0·1-14·9)	4 (11·4%) (3·2-26·7)	4 (11·4%) (3·2-26·7)	0 (0·0%) (0·0-10·0)
Myalgia	Dose 1	4 (11·4%) (3·2-26·7)	4 (11·4%) (3·2-26·7)	8 (22·9%) (10·4-40·1)	6 (17·1%) (6·6-33·6)	9 (25·7%) (12·5-43·3)	1 (2·9%) (0·1-14·9)
	Dose 2	6 (17·1%) (6·6-33·6)	2 (5·7%) (0·7-19·2)	4 (11·4%) (3·2-26·7)	11 (31·4%) (16·9-49·3)	11 (31·4%) (16·9-49·3)	1 (2·9%) (0·1-14·9)
Arthralgia	Dose 1	2 (5·7%) (0·7-19·2)	1 (2·9%) (0·1-14·9)	5 (14·3%) (4·8-30·3)	0 (0·0%) (0·0-10·0)	3 (8·6%) (1·8-23·1)	0 (0·0%) (0·0-10·0)

	Dose 2	2 (5.7%) (0.7-19.2)	1 (2.9%) (0.1-14.9)	2 (5.7%) (0.7-19.2)	4 (11.4%) (3.2-26.7)	4 (11.4%) (3.2-26.7)	0 (0.0%) (0.0-10.0)
Nausea	Dose 1	2 (5.7%) (0.7-19.2)	1 (2.9%) (0.1-14.9)	3 (8.6%) (1.8-23.1)	1 (2.9%) (0.1-14.9)	1 (2.9%) (0.1-14.9)	0 (0.0%) (0.0-10.0)
	Dose 2	3 (8.6%) (1.8-23.1)	1 (2.9%) (0.1-14.9)	1 (2.9%) (0.1-14.9)	2 (5.7%) (0.7-19.2)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)
Vomiting	Dose 1	1 (2.9%) (0.1-14.9)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	1 (2.9%) (0.1-14.9)	1 (2.9%) (0.1-14.9)	0 (0.0%) (0.0-10.0)
	Dose 2**	masked	masked	masked	masked	masked	masked

481 \* Swelling after dose 2 was reported by 1 subject only who remains masked d (0.5%, 95% CI 0.0-2.6)

482 \*\*Vomiting after dose 2 was reported by 1 subject only who remains masked (0.5%, 95% CI 0.0-2.6)

483

484 Table 3 AEs with onset during 28 days after vaccination

		<b>1 µg S</b> <b>(N = 35)</b>	<b>1 µg S+CpG</b> <b>(N = 35)</b>	<b>3 µg S</b> <b>(N = 35)</b>	<b>3 µg S+CpG</b> <b>(N = 35)</b>	<b>10 µg S</b> <b>(N = 35)</b>	<b>Placebo</b> <b>(N = 35)</b>
		<b>n (%)</b> <b>(95% CI)</b>	<b>n (%)</b> <b>(95% CI)</b>	<b>n (%)</b> <b>(95% CI)</b>	<b>n (%)</b> <b>(95% CI)</b>	<b>n (%)</b> <b>(95% CI)</b>	<b>n (%)</b> <b>(95% CI)</b>
Any	Dose 1	8 (22.9%) (10.4-40.1)	7 (20.0%) (8.4-36.9)	15 (42.9%) (26.3-60.6)	13 (37.1%) (21.5-55.1)	9 (25.7%) (12.5-43.3)	6 (17.1%) (6.6-33.6)
	Dose 2	7 (20.0%) (8.4-36.9)	3 (8.6%) (1.8-23.1)	11 (31.4%) (16.9-49.3)	10 (28.6%) (14.6-46.3)	6 (17.1%) (6.6-33.6)	9 (25.7%) (12.5-43.3)
Vaccine-related	Dose 1	2 (5.7%) (0.7-19.2)	3 (8.6%) (1.8-23.1)	3 (8.6%) (1.8-23.1)	5 (14.3%) (4.8-30.3)	3 (8.6%) (1.8-23.1)	0 (0.0%) (0.0-10.0)
	Dose 2	0 (0.0%) (0.0-10.0)	1 (2.9%) (0.1-14.9)	2 (5.7%) (0.7-19.2)	2 (5.7%) (0.7-19.2)	2 (5.7%) (0.7-19.2)	1 (2.9%) (0.1-14.9)
Serious	Dose 1*	masked	masked	masked	masked	masked	masked
	Dose 2	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	1 (2.9%) (0.1-14.9)	0 (0.0%) (0.0-10.0)	1 (2.9%) (0.1-14.9)	1 (2.9%) (0.1-14.9)
Serious vaccine-related	Dose 1	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)
	Dose 1	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)	0 (0.0%) (0.0-10.0)

485 \* Serious AE was reported by one subject only who remains masked (0.5%, 95% CI 0.0-2.6)

486

487 Table 4. GMCs of anti-S IgG (BAU/mL) and NT<sub>50</sub> by PNA (IU/mL) on day 43 and GMC ratios, vaccine to  
 488 HCS panel

		<b>1 µg S</b>	<b>1 µg S+CpG</b>	<b>3 µg S</b>	<b>3 µg S+CpG</b>	<b>10 µg S</b>
Anti-S IgG BAU/mL,	GMC	151·78	199·08	228·07	356·83	479·83
	95% CI	(108·99- 211·37)	(140·25- 282·57)	(154·22- 337·27)	(265·89- 478·88)	(360·19- 639·20)
	GMC ratio, vaccine to HCS panel	2·08	2·73	3·13	4·89	6·58
	95% CI	(0·89-4·87)	(1·16-6·43)	(1·31-7·48)	(2·12-11·31)	(2·85-15·18)
NT50 by PNA	GMC	122·23	127·92	166·54	257·70	474·35
	95% CI	(86·40- 172·91)	(85·08- 192·34)	(100·19- 276·81)	(187·01- 355·11)	(320·90- 701·19)
	GMC ratio, vaccine to HCS panel	3·37	3·52	4·59	7·10	13·07
	95% CI	(1·67-6·81)	(1·69-7·34)	(2·08-10·10)	(3·55-14·20)	(6·33-26·99)

489

490

491 Table 5. GMT and percentage of subjects with a  $\geq 4$ -fold rise from baseline (day 43) for NT<sub>50</sub> by PNA  
 492 against Wuhan strain and variants of concern

		1 $\mu$ g S	1 $\mu$ g S+CpG	3 $\mu$ g S	3 $\mu$ g S+CpG	10 $\mu$ g S	Placebo
Wuhan	GMT	n = 32 228.81 (161.74- 323.69)	n = 31 239.47 (159.27- 360.06)	n = 30 311.76 (187.56- 518.18)	n = 33 482.42 (350.08- 664.77)	n = 34 887.99 (600.72- 1,312.62)	n = 33 5.89 (4.64-7.48)
	$\geq 4$ -fold rise	N = 34 34 (100%) (89.7-100)	N = 33 31 (93.9%) (79.8-99.3)	N = 33 32 (97.0%) (84.2-99.9)	N = 33 33 (100%) (89.4-100)	N = 35 35 (100%) (90.0-100)	N = 34 2 (5.9%) (0.7-19.7)
P.1	GMT	n = 31 45.33 (32.18- 63.85)	n = 31 74.06 (48.99- 111.97)	n = 30 111.28 (72.06- 171.83)	n = 33 150.59 (111.15- 204.03)	n = 34 167.14 (120.63- 231.58)	n = 33 5.57 (4.47-6.94)
	$\geq 4$ -fold rise	N = 31 15 (48.4%) (30.2 – 66.9)	N = 31 29 (74.2%) (55/4 – 88.1)	N = 30 24 (80.0%) (61.4 – 92.3)	N = 33 29 (87.9%) (71.8 – 96.6)	N = 34 (32 (94.9%) (80.3 – 99.3)	N = 33 1 (3.0%) (0.1 – 5.8)
B.1.351	GMT	n = 32 21.00 (15.12- 29.18)	n = 30 32.34 (22.13-47.24)	n = 30 37.43 (24.77- 56.56)	n = 33 40.07 (28.09-57.17)	n = 34 43.47 (31.55-59.89)	n = 33 6.12 (4.90-7.64)
	$\geq 4$ -fold rise	N = 32 5 (15.6%) (5.3 – 32.8)	N = 40 15 (50.0%) (31.3 -68.7)	N = 30 (13 (43.3%) (30.8 – 66.5)	N = 33 16 (48.5%) (30.8 – 66.5)	N = 34 20 (58.8%) (40.7 – 75.4)	N = 33 1 (3.0%) (0.1 – 15.8)

493

494 Figure 1. Trial profile

495 Figure 2. Distribution and GMC of anti-S IgG (BAU/mL) in placebo, vaccine groups and HCS controls (A),  
496 distribution and GMC of NT<sub>50</sub> by PNA (IU/mL) in placebo, vaccine groups, and HCS controls (B),  
497 percentage of subjects with  $\geq 4$ -10-fold increase in anti-S IgG (C), and percentage of subjects with  $\geq 4$ -10-  
498 fold increase in NT<sub>50</sub> by PNA (D); numbers above data denote number of per-protocol subjects  
499 contributing data

500 Figure 3. Distribution and GMFR of fold rise in anti-S IgG from baseline (A), distribution and GMFR of fold  
501 rise in NT<sub>50</sub> by PNA from baseline (B); numbers above data denote number of per-protocol subjects  
502 contributing data

503 Figure 4. Distribution and GMT of NT<sub>50</sub> by PNA against variants of concern (day 43); numbers above data  
504 denote number of per-protocol subjects contributing data

505 Figure 5. Box plot of IFN- $\gamma$  /IL-5 ratios (ELISpot 2-colour assay); numbers above data denote number of  
506 per-protocol subjects contributing data

507

508

509


510

511

512

513

514 Figure 1



515

516

517

Figure 2






Figure 3

**A**



**B**



519

Figure 4





Figure 5



520

521